CN1813855A - Medicine for treating cardio-cerebrovascular disease - Google Patents

Medicine for treating cardio-cerebrovascular disease Download PDF

Info

Publication number
CN1813855A
CN1813855A CN 200510022121 CN200510022121A CN1813855A CN 1813855 A CN1813855 A CN 1813855A CN 200510022121 CN200510022121 CN 200510022121 CN 200510022121 A CN200510022121 A CN 200510022121A CN 1813855 A CN1813855 A CN 1813855A
Authority
CN
China
Prior art keywords
medicine
radix rhodiolae
extrtact
cerebrovascular disease
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510022121
Other languages
Chinese (zh)
Other versions
CN100391484C (en
Inventor
周裕程
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUODIKANG PHARMACEUTICAL INDUSTRY Co Ltd TIBET
Original Assignee
NUODIKANG PHARMACEUTICAL INDUSTRY Co Ltd TIBET
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NUODIKANG PHARMACEUTICAL INDUSTRY Co Ltd TIBET filed Critical NUODIKANG PHARMACEUTICAL INDUSTRY Co Ltd TIBET
Priority to CNB2005100221217A priority Critical patent/CN100391484C/en
Publication of CN1813855A publication Critical patent/CN1813855A/en
Application granted granted Critical
Publication of CN100391484C publication Critical patent/CN100391484C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a Chinese medicine for effectively curing the diseases of angiocardiopathy, cerebrovascular disease, migraine, diabetes and menopausal syndrome of women. Said Chinese medicine is made up by using rhodiola sacra extract as main raw material and adding medicinal auxiliary material through a certain preparation process. Besides, said invention also provides the concrete steps of said preparation process.

Description

The medicine of treatment cardiovascular and cerebrovascular disease
Technical field:
The present invention is relevant with the medicine of treatment cardiovascular and cerebrovascular disease, migraine, diabetes, climacteric syndrome.
Background technology:
The thoracic obstruction (coronary heart disease, angina pectoris), disease sees chest pain, uncomfortable in chest, cardiopalmus, breathes hard, dizzy, weak, insomnia and dreamful sleep etc., coronary heart disease has a lot of similarly records in the Ancient Times in China medical literature, as having in " opinion piece of writing when element is asked the visceral-qi method ": " heart patient, chest pain, discomfort and fullness in the hypochondrium; pain over the hypochondrium; pain between eagle back of the body omoplate, pain in the medial sides of both arms ", this is actually the record to anginal painful area." Ling Shu Miraculous Pivot or Divine Axis fault disease " piece of writing is said: " angina pectoris, blue or green to joint, very pained in the hands, onset of disease in the evening and dying in the next morning ", illustrate and be familiar with that this situation is similar to myocardial infarction to the seriousness of anginal serious symptom and prognosis thereof is existing." Medical Treasures of the Golden Chamber obstruction of qi in the chest and cardialgia lose heart disease " has " disease of the thoracic obstruction; dyspnea and expectoration, the pain over the chest and back is losed heart ... " and records such as " unable to tie down due to obstruction of QI in the chest, chest pain radiating to the back ", have recognized that coronary artery pathological changes can cause dyspnea, has described the symptom that is equivalent to the coronary heart disease heart failure." principle is specified in tcm clinical practice research " that Ministry of Health of the People's Republic of China develops and publishes spells out, and the thoracic obstruction is equivalent to coronary heart disease, the angina pectoris of modern medicine.During primary disease is more common in, the old people.Over fifty, the kidney qi degradation as kidney yang deficiency, then can not be inspired YANG of five ZANG-organs, can cause deficiency of heart-QI or flaccidity of the heart-yang; Deficiency of kidney-YIN then can not nourish the moon of the five internal organs, can cause the heart-yin in-fighting.The heart-yin is lost empty, flaccidity of the heart-yang, and it is smooth that QI-blood circulation is lost, so that the heart arteries and veins stasis of blood is stagnant, and the thoracic obstruction takes place.And inward invasion of pathogenic cold, improper diet, disorder of emotion etc., it is real all can to form mark on the basis of deficiency in origin, as cold coagulation, the stagnation of QI, blood stasis, stagnation of phlegm, and stagnated chest-YANG more, stagnating heart meridian has increased the weight of the thoracic obstruction (coronary heart disease, angina pectoris).Thereby the many simulataneous insufficiency and excessive of the thoracic obstruction (coronary heart disease, angina pectoris) clinical manifestation.With regard to empty, be this with the deficiency of vital energy.With regard to reality, stagnating with the stasis of blood is urgency.Control to take a tonic or nourishing food to build up one's health set upright, blood circulation promoting and blood stasis dispelling, emergency is taken into account, real good method for the treatment thoracic obstruction (coronary heart disease, angina pectoris), it is more to treat cardiovascular medicament at present, but side effect is all arranged mostly, and can not be used for the treatment of diabetes, climacteric syndrome etc.
Radix Rhodiolae QI invigorating: " brilliant pearl book on Chinese herbal medicine " record: " the Radix Rhodiolae sweet in the mouth ..., the nourishing QI invigorating ".The tonic that is considered as among the people is fried in shallow oil water with rhizome and is taken to eliminate the fatigue that heavy physical labour brings, treatment physical weakness, diseases such as general weakness.The former Russian scholar studies show that Radix Rhodiolae has " strengthening the body resistance " effect of similar Radix Ginseng, and is being better than Radix Ginseng aspect the enhance immunity effect.This product resisting fatigue, oxygen lack resistant function are good, have now developed a lot of Radix Rhodiolae tonic invigorators, not only in Tibet, in China's extensive use, in the former Soviet Union, also be used as diver, pilot, athlete, spaceman and national top leader's health product.
Summary of the invention:
The objective of the invention is provides a kind of and not only can treat cardiovascular and cerebrovascular disease in order to overcome above deficiency, and it is good to treat therapeutic effect such as migraine, diabetes, climacteric syndrome, has no side effect free of contamination medicine.
The object of the present invention is achieved like this:
The present invention treats the medicine of cardiovascular and cerebrovascular disease, this medicine is that Radix Rhodiolae extrtact and adjuvant is formulated, the preparation method of Radix Rhodiolae extrtact is to be to decoct with water secondary after with the section of Radix Rhodiolae rhizome under 0 ℃~15 ℃ the condition in 3600~4500 meters of height above sea level, temperature, decocting time is 70~120 minutes for the first time, decocting time is 45~80 minutes for the second time, collecting decoction, filter, it is 1.1~1.40 that filtrate is concentrated into 40 ℃ of temperature relative densities, spray drying promptly makes Radix Rhodiolae extrtact.
The above-mentioned decocting time first time is 90 minutes, and decocting time is 60 minutes for the second time.
Above-mentioned adjuvant is a starch, and the weight ratio of Radix Rhodiolae extrtact and starch is 1: 0.35~0.45, starch is added adopt wet method or fluidized granulation in the Radix Rhodiolae extrtact, is dried to water content less than 4%, incapsulates, and makes the capsule formulation medicine.
Above-mentioned adjuvant is a starch, and the weight ratio of Radix Rhodiolae and starch is 192~216: 64~88, adds starch in the Radix Rhodiolae extrtact, granulate, and tabletting, the bag film-coat promptly makes the tablet form medicine.
Above-mentioned adjuvant is dextrin, Icing Sugar, the weight ratio of Radix Rhodiolae extrtact and dextrin, Icing Sugar is 40~80: 150~300: 700~800, behind Radix Rhodiolae extrtact and dextrin, Icing Sugar mix homogeneously, add and stir, wet method or fluidized granulation, sieve, be dried to water content and be 4% when following the granular pattern medicine.
Above-mentioned adjuvant is antiseptic, correctives, the weight ratio of Radix Rhodiolae extrtact and antiseptic, correctives is 50~70: 0.5~1.5: 400~450, Radix Rhodiolae extrtact, antiseptic, correctives are mixed, add water boil, leave standstill, filter, it is 15~25 times of Radix Rhodiolae consumption that filtrate adds water to consumption again, oral liquid formulation.
Above-mentioned antiseptic is sorbic acid or sodium benzoate or nipalgin, and correctives is Mel or white sugar or Folium Stevlae Rebaudianae.
Radix Rhodiolae also has invigorating blood circulation, calms the nerves, effect such as pain relieving except that having the QI invigorating effect.The Four-Volume Medical Code has been put down in writing the blood circulation-promoting functions of Radix Rhodiolae, with controlling lip and the palm of the hand is blue.Chemical analysis discovers that Radix Rhodiolae contains multiple active ingredients such as flavone.And compositions such as flavone can coronary artery dilator, increase coronary flow, reduce myocardial oxygen consumption, anticoagulant, antithrombotic formation etc., thereby promoting blood flow is eliminated the stasis of blood and is stagnated.Effects such as the calming the nerves of Radix Rhodiolae, pain relieving, closely related with the inrigorating qi and promoting blood circulation effect of Radix Rhodiolae.The prosperous blood of gas is alive, and in the arteries and veins that passes unimpeded, gains in depth of comprehension blood is supported then refreshing from peaceful, and blood beniol alive then pain can end.Radix Rhodiolae also has the effect of the former state of adaptation, and the ill mark sense normal condition that the different causes of disease are caused changes.Realize " YIN and YANG in a relative equilibrium " " element is asked the vital QI of the body connecting with natural QI opinion " day: " wanting of negative and positive, sun is close to be solid.Both discord, if the spring do not have the autumn, if the winter do not have the summer, thereby and it, be to call the rule of sage.YIN and YANG in a relative equilibrium, life activities being normally maintained ".In sum, Radix Rhodiolae energy benefiting QI for activating blood circulation, ataralgesia, YIN and YANG balance regulating are suitable for the treatment of angina pectoris (thoracic obstruction).The present invention has selected the elaboration Radix Rhodiolae in the Radix Rhodiolae for use, a kind ofly originate in 3600~4500 meters high protophyte of Tibet plateau height above sea level, it contains rhodioside and the cruel alcohol of glycoside unit is pollution-free, adopted special preparation method simultaneously, the extraction that can satisfy effective ingredient is complete, and not facile hydrolysis and enzymolysis guarantee that the product curative effect prepares the general flavone content height, have kept the medicine of the present invention of effective ingredient simultaneously.
Total flavones composition contained in the medicine of the present invention has coronary artery dilator, resists myocardial ischemia, and improves cardiac function, and microcirculation improvement reduces blood viscosity, accelerates effects such as red cell velocity.Through Tibet Autonomous Region's the People's Hospital's prerun, coronary heart disease, hypertension, cerebrovascular disease are truly had curative effect through 30 routine case statistical confirmations medicament capsule of the present invention.Show that through the clinical of Tibet altitude sickness institute of cardiovascular diseases 100 routine cases medicine of the present invention reaches 98% to the total effective rate of plateau pneumochysis and altitude sickness.As the Tibet plateau biological study Peng * *, the woman, 52 years old, suffer from surplus the coronary heart disease existing ten year, often occur pained, uncomfortable in chest, symptom such as breathe hard; Simultaneously, also with the neurasthenia, diseases such as myasthenia of limbs.Take capsule of the present invention every day three times, each 2, after one month, above-mentioned symptom is obviously alleviated.After continuing to take one month, symptom all takes a turn for the better, and is now also working on.
Capsule formulation medicine pharmacological testing of the present invention shows that medicine of the present invention can obviously reduce the degree of ischemia and the ischemia scope of rat experiment myocardial ischemia, reduces infraction.Point out medicine of the present invention to coronary heart disease, angina pectoris has preventive and therapeutic effect.Medicine of the present invention has the effect of tangible reduction hyperlipidemia rats serum TC, TG, LDL-C, and Serum HDL-C is raise.Modern science thinks that serum TC content height can quicken atherosclerotic process, and TG and LDL-C are the risk factors that coronary heart disease produces, and the HDL-C content height in the blood atherosclerosis then takes place and causes that cardiovascular diseases's danger is just little.Point out medicine of the present invention that the cardiovascular diseases is had significant protective effect.
Medicine of the present invention has mean arterial pressure, the left chamber maximum collapse of 1 year rat model after the obvious rising myocardial infarction and presses, remarkable rising left indoor pressure rising maximum rate and left indoor pressure decline maximum rate, obviously increase the animal cardiac output, improve cardiac index, significantly increase the Coronary vein oxygen content, it is poor to dwindle a crown moving vein oxygen content, reduces myocardial oxygen consumption, and dog heart rate and coronary flow are not had obvious influence.Prompting the present invention has the effect of control and treatment ischemic heart desease.
The animal acute toxicity test result of capsule formulation medicine of the present invention shows: Kunming mouse is irritated stomach with receptive maximum 0.4ml/10g once, dosage is 16g/kg or 112g (crude drug amount)/kg, observed seven days continuously for 522 times that are equivalent to the clinical daily dose 0.21g of people (crude drug amount)/kg, mice behavior, hair, diet, body weight, defecation there is no unusually, and none is only dead.
The long term toxicity test of capsule formulation medicine of the present invention shows: capsule formulation medicine of the present invention promptly is equivalent to 1.4g (crude drug amount)/kg, 7.0g (crude drug amount)/kg and 35.0g (crude drug amount)/kg respectively (by clinical everyone every day three times with three dosage group 0.2g/kg, 1.0g/kg, 5.0g/kg, 2/time meters, be equivalent to 6.6,33.3 and 166.0 times of clinical every day of dosage respectively) give 12 weeks of rat continuous irrigation stomach, be administered once every day, 6 days weekly.The ordinary circumstance of rat, body weight, hematological indices, organ coefficient, blood parameters are not all found toxic action.Drug withdrawal 2 all backs convalescent period result of the tests are not found delayed toxicity.Each organs and tissues morphocytology of administration phase and convalescent period histological examination is normal, the little lipid cavity that as seen three dosage treated animals of capsule formulation medicine of the present invention adrenal gland all fills the air, corpus luteum and follicle number increase in ovum, the nest, and degree is similar, does not have obvious dose relationship.Point out capsule formulation medicine of the present invention to have the effect that strengthens adrenal gland and ovarian function.In sum, show that the toxicity of capsule formulation medicine of the present invention is very little, safety range is bigger, and clinical used dosage is safe.
Capsule formulation medicine of the present invention is used for the treatment of migrainous observation of curative effect:
Migraineur's 30 examples are selected in outpatient service at random.Man's 11 examples, women 19 examples, age 20-70 year, 45 years old mean age, the course of disease did not wait in 3 months-30 years, its mild or moderate 2 examples, moderate 15 examples, severe 13 examples.30 example inclined to one side the oral capsules of the present invention of patient each 2 (560mg), every day 3 times, one month course of treatment, the result shows: (1) pharmaceutical capsules of the present invention can obviously improve patient's symptom of having a headache, and total effective rate reaches 93.3%; (2) pharmaceutical capsules of the present invention has certain influence to platelet aggregation; (3) during taking, do not find any toxic and side effects, take safely (see Table 1, table 2).
Table 1: the back clinical improvements situation of taking medicine
Total routine number Produce effects Effectively Invalid Obvious effective rate Total effective rate
The example number The example number The example number
30 examples 17 56.7 11 36.7 2 6.7 56.7 93.3
The variation of platelet aggregation after table 2 is taken medicine
Before the treatment After the treatment The P value
Platelet aggregation (%) 70.3±21.2 31.7±19.3 <0.05
With contrast P<0.05 before the treatment, illustrate that there is significant difference in the treatment front and back, find in the experiment that platelet aggregation decline degree and headache alleviation degree are proportionate.
At period in a medicine, do not find that gastrointestinal upset appears in the patient, toxic and side effects such as anaphylaxis.
Capsule medicine treatment climacteric syndrome of the present invention 53 routine clinical observations:
53 examples all are the outpatient, 19 examples of course of disease half a year, 18 examples of half a year~1 year, 14 examples of half a year~1 year half, 1 year 2 example more than half.Oral 1~2,3 times on the 1st warm water delivery services, one month is 1 course of treatment, also can cooperate oryzanol 20mg, 3 times on the one, vitamin 1320mg, 3 times on the one.This organizes recovery from illness 18 examples in 53 examples, 24 examples that take effect, and effective 7 examples, invalid 4 examples, total effective rate is 92.6%.
Model case:
The Wang, woman, 50 years old, married, the workman. main suit, insomnia and dreamful sleep, warm sweating half a year, increased the weight of history of present illness 1 month: the patient before half a year no any inducement insomnia and dreamful sleep appears, cardiopalmus is warmed sweating, and is easily frightened, once took medicine treatments such as oryzanol, vitamin B1, symptom does not subtract, nearly 1 month sx, sometimes lie awake all night, clothes are stable can fall asleep.Paroxysmal is warmed, sweating, meet some minor matters then cardiopalmus, tremble with fear.Have a medical check-up: physically well develop, sanity, body of the tongue are light red, thin white fur of tongue, arteries and veins are dizzy thin.Electrocardiogram prompting: roughly normal.Western medicine diagnose: climacteric syndrome, tcm diagnosis: menopausal syndrome.Advise patient's regulating spirit and emotion by oneself, suitable daily life is struck a proper balance between work and rest, and treats and examines after 1 month again, warms sweating cardiopalmus and disappears, and it is still not good enough to sleep, and continues treatment 2 months, and all diseases of patient disappear, and for consolidating curative effect, advise the patient to take medicine 1 month again.
Medicine combined with chemotherapy of the present invention is to the terminal cancer clinical observation:
In, advanced lung cancer lost the surgical radical treatment chance, and chemotherapy effect is also unsatisfactory.More side reaction is arranged again in chemotherapy process, treatment is interrupted, bone marrow depression is a big obstacle in the treatment in the chemotherapy, secondly causes the patient not take food for serious gastrointestinal reaction, and the body resistivity further weakens.In addition, patients with lung cancer cellular immunity function often is in low state, and chemotherapy can cause immunologic function to upgrade inhibition, and therefore making great efforts to improve above-mentioned condition is key subjects on the lung cancer therapy.
In * * * the 12 routine medium and advanced lung cancers of being in hospital are carried out chemotherapy between year August-December to use oral liquid 10ml of the present invention simultaneously, 3 times on the 1st oral, obeyed altogether 60 days, meter small cell lung cancer 4 examples, nonsmall-cell lung cancer 8 examples (male 10 examples, woman's 2 examples), 59.2 years old mean age, it (is VP16 one etoposide that the small cell lung cancer chemotherapy is used the VP/PT scheme, the DDP-cisplatin) 2 cycles, nonsmall-cell lung cancer (8 example), chemotherapy is used CAP scheme (CTX-cyclophosphamide, ADM amycin, DDP cisplatin) (see Table 3, table 4.)
Other establishes transfers over simple chemotherapy advanced lung cancer 8 examples at random and is matched group (seeing Table 4).
Observe patient's gastrointestinal reaction, feel sick, vomiting, alopecia, symptom such as smart neuritis not, detect hemogram weekly, liver, renal function, t lymphocyte subset group, X line rabat, body weight etc.
Table 3 12 routine lung cancer therapy catalogs
Admission number Name Age Sex Diagnosis typing The course of disease Method The result
9308629 The end * * 75 The man The center scale cancer 3 months CAP+ oral liquid of the present invention The remission focus is dwindled
9328076 Dong * * 62 The man The center scale cancer 2 months CAP+ oral liquid of the present invention The remission focus is dwindled
9310603 Lu * * 66 The man Peripheral adenocarcinoma vertigo moves 3 months CAP+VP16+BCUN+ oral liquid of the present invention Vertigo moves focus and dwindles, remission
9311135 Cui * * 63 The woman Center adenocarcinoma superior vena cava tumor 3 months CAP+VP16+ oral liquid of the present invention The remission focus is dwindled
9307835 The king * * 60 The man Alveolar adenocarcinoma 2 months CAP+VP16+ oral liquid of the present invention Alleviate
9309141 The field * * 37 The man The center undifferentiated carcinoma 3 months DDP+VP16+ oral liquid of the present invention The remission focus is dwindled
9311751 Open * * 60 The woman The center scale cancer 2 months CTX, VP16, DDP, VCR+ oral liquid of the present invention The remission focus is dwindled
9312937 Zhu * * 68 The man The center scale cancer 3 months CTX, DDP, VP16+ oral liquid of the present invention Take a turn for the better, alleviate
9303172 Lee * * 47 The woman Undifferentiated carcinoma on every side 3 months DDP, VP16+ oral liquid of the present invention Symptom improvement focus is dwindled
9301774 Eventually * * 59 The man The center undifferentiated carcinoma 4 months DDP, VP16+ oral liquid of the present invention Symptom improvement focus is dwindled
9301442 The king * * 47 The man The center undifferentiated carcinoma 3 months DDP, VP16+ oral liquid of the present invention Symptom improvement focus is dwindled
9302772 In vain * * 67 The woman The center scale cancer 3 months CAP+ oral liquid of the present invention The symptom improvement state of an illness is dwindled
A 12 routine pulmonary carcinoma 1-2 cycle chemotherapy was taken oral liquid of the present invention 2 months, and symptom has improvement in various degree, and focus all has dwindles, stable disease, and 8 routine appetite are promoted, weight increase, all case WBC are stabilized in 5.6+1.2 * 10 9/ L, platelet 14 ± 6 * 10 9/ L, 10 examples do not have nauseating, vomiting, only alopecia appears in 2 examples, and 1 example has the peripheral nerve inflammation, and 12 examples are the tolerance chemotherapy all, and nothing 1 example is interrupted.CD before the t lymphocyte subset group chemotherapy during this time 4(helper T cell), CD 4/ CD 8(suppressor T cell) ratio descends, obey oral liquid of the present invention after 6 examples 4 routine CD are arranged 4/ CD 8Ratio rises.
Do not obey medicine group of the present invention relatively with the 8 routine medium and advanced lung cancer chemotherapy of being in hospital, this group WBC on average drops to 3.8 * 10 9/ L.6 examples have alopecia, neuritis slightly not in 8 examples, and all cases all have nausea and vomiting, and renal dysfunction appears in 2 examples.Chemotherapeutic period T lymphocyte CD 4, CD 4/ CD 8Ratio obviously descends, wherein 4 routine livers, renal dysfunction, and WBC descends 4.0 * 10 9/ L is following and interrupt chemotherapy, worsens deadly, and all the other 4 routine symptoms have alleviation slightly, but focus is not seen obviously and dwindled (seeing Table 4).
In taking courses of pharmaceuticals of the present invention, do not find tangible chemotherapy side effect, some non-tumour patients are taken oral liquid of the present invention and are not found that liver, kidney and hemopoietic function are impaired.
Malignant tumor person's immunocompetence descends; the chemotherapeutic period immunologic function is low especially; therefore protect body immunity; safeguard hemopoietic system; making in the chemotherapy digestive system reaction reduce to minimum is a big problem in the chemotherapy of tumors, because of Radix Rhodiolae has the body hypoxia-bearing of making, and resisting fatigue; antitoxic action makes it the infringement that body can better tolerate tumor.Radix Rhodiolae to nervous system dual regulation and anti-peroxidation effect, make it tumour patient and can improve toleration chemotherapy, this has strengthened curative effect with oral liquid of the present invention during organizing clinical 12 routine lung cancer chemotherapies, toxic reaction obviously reduces than matched group, the oral liquid of the present invention pulmonary carcinoma adjuvant therapy medicaments of can yet be regarded as is described, its application value is arranged.
Medicine of the present invention has the auxiliary treatment effect to schizophrenia:
Aspiration is taken medicine person of the present invention, all meet classify schizophrenia diagnosis totally 21 examples (man 11, women 10) of clinical description and diagnostic point the 10th edition (ICD-10) of the 2nd edition revised edition of Chinese mental sickness classification schemes diagnostic criteria (CCMD-2-R) and International Classification of Diseases spirit and behavior disorder.16~49 years old age, average 28.71 ± 6.99 years old, under the constant prerequisite of former clothes psychosis species and dosage, add 2/time of capsules of the present invention (560mg), every day three times, serve on 60 days.Adopt own control, strengthen from spiritual vigor, memory improves, and muscle power increase, antipsychotic drug reactions change, sexual function change, the several aspects of side effect, by the regular further consultation of outpatient service, by patient and common evaluation of family members and the continuous observed and recorded registration of attending doctor.
The result: it is 100% that spiritual vigor strengthens, and memory improves 76.19%; Muscle power increases by 57.14%; 8 examples have psychosis side reaction person in various degree, and all readme alleviates, and wherein 1 routine TD person takes a turn for the better obviously, and 3 routine sexual impotence also all have improvement.Wherein 1 example returns to the preceding sexual function state of disease fully, and patient and family members' excitement are very.Whole 21 examples there is no side reaction and occur.Electrocardiogram and chemically examine also no abnormality seen therebetween.
Medicine of the present invention not only can be treated cardiovascular and cerebrovascular disease, and can also treat migraine, diabetes, climacteric syndrome and enhancing body immunity etc., and therapeutic effect is good, and safety has no side effect.
The specific embodiment:
Embodiment 1:
Present embodiment 1 capsule-type medicine be with through the selection, washing, exsiccant 2000 gram Radix Rhodiolae rhizomes become to be cut to the sheet of 1~2cm, 3600~3800 meters of height above sea level, temperature is to decoct secondary under 0 ℃~15 ℃ conditions, before, twice of back amount of water respectively is 8 times and 6 times of Radix Rhodiolae rhizome amount, decocted 90 minutes for the first time, decoct for the second time 60 minutes (its every boiling temperature is 92~93 ℃), collecting decoction, filter with ceramic membrane (0.5 μ m), it is 1.25~1.30 that filtrate is concentrated into 40 ℃ of temperature relative densities, carries out spray drying system with Highspeedcentrifugingandsprayingdrier and promptly makes Radix Rhodiolae extrtact.Radix Rhodiolae extrtact and medical starch are prepared burden and mixing by 10: 4 weight ratio; with 75% (volume ratio) ethanol is wetting agent, with full-automatic wet method mechanism grain or (fluidized granulation), to be dried to water content be that 3% back filled capsules is made 1000 capsule-type medicines of the present invention.
Embodiment 2:
Present embodiment 2 tablet medicines are formulated in extract and starch with the red scape in embodiment 1 Zisco sky.With the weight ratio of Radix Rhodiolae extrtact and medical starch is 202: 78 batching mixings, wet method or fluidized granulation carry out tabletting (tabletting pressure 16KN with qualified granule with high speed tablet press, 100,000 slices/hour of machine speeds), the film coating powder of producing with the permanent Tai Gaofenzibaomocailiaochang in Chengdu wraps film-coat then, promptly makes tablet.
Embodiment 3:
Present embodiment 3 granular pattern medicines are formulated with the Radix Rhodiolae extrtact among the embodiment 1 and dextrin, Icing Sugar.Pressing weight ratio 60: 200: the 740 batching mixing of Radix Rhodiolae extrtact and dextrin, Icing Sugar, is wetting agent with an amount of 70% (volume ratio) medicinal alcohol, adds water and stirs, and wet method or fluidized granulation sieve then, is dried to water content and is 4% when following.
Embodiment 4:
Present embodiment 4 oral liquid type medicines are formulated with the Radix Rhodiolae extrtact among the embodiment 1 and sorbic acid and Mel.Get 60g Radix Rhodiolae extrtact, 420g Mel, 1g sorbic acid, add water 500ml and stir, boil, leave standstill, filter, add water to 1000ml.This peroral dosage form is taken easily, and is all-ages, easy to carry; Can cover the bitter taste of medicine discomfort, be convenient to take; The bioavailability of medicament height, rapid-action.
The various embodiments described above are that foregoing of the present invention is further described, but this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to the foregoing description.All technology that realizes based on foregoing all belong to scope of the present invention.
Table 4: oral liquid combined with chemotherapy observation of curative effect synopsis of the present invention
Grouping Remission rate Groups such as toxicity Disease progression Interrupt chemotherapy Life quality karnkofsky scoring WBC sum grand mean The PCT meansigma methods Liver moves AST.ALT BUN CD CD 2/CD 2
The group of taking medicine 12 examples 100% 0 degree, 4 routine I degree 6 routine II degree 2 examples 0 0 72 5.8×10/L 98×10/L 12 examples are normal 12 examples are normal Normal 2 examples of 10 examples are low
Matched group 8 examples 37% III degree 4 routine IV degree 4 examples 4 4 62 3.4×10/L 65×10/L Unusual 2 normal 6 8 examples are unusual Normal 2 examples of 2 examples are low
* toxic reaction grade
0 degree: no any toxic reaction of observing:
The I degree: minor response, can tolerate, do not need drug withdrawal.
The II degree: significant reaction, organ dysfunction needs decrement or drug withdrawal, give ancillary method after, can recover in a short time.
The III degree: seriously reaction that can be fatal, necessary drug withdrawal can recover after the positive treatment.
IV degree: because of drug toxicity causes death.
Estimate life quality mainly according to the Karnkofsky standards of grading.

Claims (7)

1, the medicine of treatment cardiovascular and cerebrovascular disease, this medicine is that Radix Rhodiolae extrtact and adjuvant is formulated, the preparation method of Radix Rhodiolae extrtact is to be to decoct with water secondary after with the section of Radix Rhodiolae rhizome under 0 ℃~15 ℃ the condition in 3600~4500 meters of height above sea level, temperature, decocting time is 70~120 minutes for the first time, decocting time is 45~80 minutes for the second time, collecting decoction, filter, it is 1.1~1.40 that filtrate is concentrated into 40 ℃ of temperature relative densities, spray drying promptly makes Radix Rhodiolae extrtact.
2, the medicine of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 is characterized in that decocting time is 90 minutes for the first time, and decocting time is 60 minutes for the second time.
3, the medicine of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 or 2, it is characterized in that adjuvant is a starch, the weight ratio of Radix Rhodiolae extrtact and starch is 1: 0.35~0.45, starch is added employing wet method or fluidized granulation in the Radix Rhodiolae extrtact, be dried to water content less than 4%, incapsulate, make the capsule formulation medicine.
4, the medicine of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 or 2, it is characterized in that adjuvant is a starch, the weight ratio of Radix Rhodiolae extrtact and starch is 192~216: 64~88,. in Radix Rhodiolae extrtact, add starch, granulate, tabletting, the bag film-coat promptly makes the tablet form medicine.
5, the medicine of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 or 2, it is characterized in that adjuvant is dextrin, Icing Sugar, the weight ratio of Radix Rhodiolae extrtact and dextrin, Icing Sugar is 40~80: 150~300: 700~800, behind Radix Rhodiolae extrtact and dextrin, Icing Sugar mix homogeneously, add and stir, wet method or fluidized granulation sieve, be dried to water content and be 4% when following the granular pattern medicine.
6, the medicine of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 or 2, it is characterized in that adjuvant is antiseptic, correctives, the weight ratio of Radix Rhodiolae extrtact and antiseptic, correctives is 50~70: 0.5~1.5: 400~450, Radix Rhodiolae extrtact, antiseptic, correctives are mixed, add water boil, leave standstill, filter, it is 15~25 times of Radix Rhodiolae consumption that filtrate adds water to consumption again, oral liquid formulation.
7, the medicine of treatment cardiovascular and cerebrovascular disease as claimed in claim 6 is characterized in that antiseptic is sorbic acid or sodium benzoate or nipalgin, and correctives is Mel or white sugar or Folium Stevlae Rebaudianae.
CNB2005100221217A 2005-11-23 2005-11-23 Medicine for treating cardio-cerebrovascular disease Active CN100391484C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100221217A CN100391484C (en) 2005-11-23 2005-11-23 Medicine for treating cardio-cerebrovascular disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100221217A CN100391484C (en) 2005-11-23 2005-11-23 Medicine for treating cardio-cerebrovascular disease

Publications (2)

Publication Number Publication Date
CN1813855A true CN1813855A (en) 2006-08-09
CN100391484C CN100391484C (en) 2008-06-04

Family

ID=36906287

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100221217A Active CN100391484C (en) 2005-11-23 2005-11-23 Medicine for treating cardio-cerebrovascular disease

Country Status (1)

Country Link
CN (1) CN100391484C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732394A (en) * 2008-11-07 2010-06-16 羊敏 Tibetan medicament for treating depression and phrenesis (schizophrenia) and preparation method thereof
CN104432067A (en) * 2014-12-22 2015-03-25 威海百合生物技术股份有限公司 Health food for relieving female climacteric syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268323C (en) * 2004-04-30 2006-08-09 成都优他制药有限责任公司 Rhodiola sacra soft capsule and its preparation
CN1586510A (en) * 2004-07-26 2005-03-02 张元茂 Rhodiola sacra capsule containing glucoside and its preparing method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732394A (en) * 2008-11-07 2010-06-16 羊敏 Tibetan medicament for treating depression and phrenesis (schizophrenia) and preparation method thereof
CN104432067A (en) * 2014-12-22 2015-03-25 威海百合生物技术股份有限公司 Health food for relieving female climacteric syndrome

Also Published As

Publication number Publication date
CN100391484C (en) 2008-06-04

Similar Documents

Publication Publication Date Title
CN102028900B (en) Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof
CN1899379A (en) External plaster for treating child cold diarrhea and preparing method
CN100493572C (en) Composition of medication for treating diabetes
CN102631595B (en) Medicament for treating II-type diabetes mellitus and preparation method thereof
CN101244205A (en) Vein relaxing antihypelipidemic product based on reestablishment entatic state theory and preparation method
CN104857436B (en) Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application
CN103622027B (en) A kind of hypoglycemia healthcare food composition
CN100391484C (en) Medicine for treating cardio-cerebrovascular disease
CN102671056B (en) Chinese medicinal composition for treating hepatitis and preparation method thereof
CN102228620B (en) Chinese medicinal compound preparation having the functions of supplementing iron and enriching the blood and preparation method thereof
CN1990033A (en) Drug for treating hypertension, dense blood and arteriosclerosis
CN101342346A (en) Drop pill for treating stenocardia caused by coronary disease
CN1063649C (en) Red ginseng and hawthorn fruit health-care wine
CN105343506A (en) Method for preparing composition for treating type-2 diabetes
CN106729304B (en) A kind of Chinese medicine for mitigating fasting or side reaction of dieting and preparation method thereof
CN104474103A (en) Natural plant hypoglycemic agent and preparation method thereof
CN100339119C (en) Traditional Chinese medicine prepns. for treating diabete
CN100455317C (en) Medicament for treating type 2 diabetes
CN1276764C (en) Liu-Wei-Bu-Xue granule for invigorating blood contg. six herbal medicines and its prepn. method
CN104524003A (en) Traditional Chinese medicine composition with golden camellia and radix pueraiae
CN103656196A (en) Traditional Chinese medicine composition for treating cutaneous pruritus caused by diabetes and preparation method thereof
CN1233361C (en) Traditional Chinese medicine composition for treating cardiovascular disease
CN1183933C (en) Medicine for treating incomplete kidney function and its prepn
CN106728828A (en) A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease
CN1814171A (en) Medicine for treating renal incompetence

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant